Clinical epidemiology -- how important now?

Binder, V
May 2005
Gut;May2005, Vol. 54 Issue 5, p574
Academic Journal
The article focuses on the putative risk of haematopoietic cancer in relation to modern strong immunosuppressive treatment in inflammatory bowel disease. The natural history of a chronic disease should ideally be the background for any therapeutic trial. Modern information technology has facilitated the creation of large databases which, combined with epidemiologically correct data collection, give the possibility of depicting prognosis and the long term course of chronic diseases during a given treatment regimen. With regard to inflammatory bowel disease, the goals for medical management of these chronic diseases are mandatory.


Related Articles

  • Risk of haematopoietic cancer in patients with inflammatory bowel disease. Askling, J; Brandt, L; Lapidus, A; Karlén, P; Björkholm, M; Löfberg, R; Ekbom, A // Gut;May2005, Vol. 54 Issue 5, p617 

    Background and aims: Several chronic inflammatory conditions are associated with an increased risk of lymphoma. Whether this applies to inflammatory bowel disease (IBD) is still unclear but of paramount interest, particularly in the safety evaluation of newer immunosuppressive drugs. Reports...

  • No increased cancer risk with immunosuppressants in IBD.  // Reactions Weekly;2/10/2007, Issue 1138, p4 

    The article discusses research being done on the risk of developing cancer in patients with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, who received immunosuppressants. It references a study by Masunaga et al in the January 2007 issue of "Annals of...

  • Clostridium difficile and Inflammatory Bowel Disease (IBD). Deresinski, Stan // Clinical Infectious Diseases;9/1/2009, Vol. 49 Issue 5, piii 

    The article presents the analysis of the author on the study conducted regarding an assessment for the relations of Clostridium (C) difficile and inflammatory bowel disease (IBD). The researchers have determined the association of C. difficile in patients with IBD as the rate of carriage...

  • Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. Kverka, Miloslav; Rossmann, Pavel; Tlaskalova-Hogenova, Helena; Klimesova, Klara; Jharap, Bindia; de Boer, Nanne K.; Vos, Rene M.; van Bodegraven, Adriaan A.; Lukas, Milan; Mulder, Chris J. // BMC Gastroenterology;2011, Vol. 11 Issue 1, p47 

    Background: Oral thiopurines are effective and widely used in treatment of inflammatory bowel disease (IBD) in humans, although their use is limited due the development of adverse events. Here, we examine the efficacy and toxicity of oral treatment with 6-tioguanine (6-TG) and azathioprine (AZA)...

  • IBD patients face increased skin cancer risk.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p35 

    The article reports on the findings of two studies on the increased skin cancer risk in patients with inflammatory bowel disease (IBD). It notes that the study led by Laurent Peyrin-Biroulet has found the risk of nonmelanoma skin cancer (NMSC) in patients with IBD, which is intensified by the...

  • Do inflammatory bowel disease therapies cause cancer? Balzola, Federico; Cullen, Garret; Hoentjen, Frank; Ho, Gwo-Tzer; Russell, Richard // Inflammatory Bowel Disease Monitor;2013, Vol. 13 Issue 4, p164 

    The article discusses the side effect of thiopurines or anti-tumor necrosis factor agents to treat patients with inflammatory bowel diseases (IBD). It examines the role of anti-inflammatory drugs to reduce the risk of cancer associated with the risk of neoplasia and the duration of inflammation....

  • Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Beaugerie, Laurent // Gut;Apr2012, Vol. 61 Issue 4, p476 

    The article presents information on the treatment of inflammatory bowel disease (IBD) and highlights that the risk of cancer is associated with it. It mentions that immunosuppression and inflammation are the main cause of carcinogenesis due to IBD. It also mentions that the main challenge of the...

  • New Drug Delivery Systems in Inflammatory Bowel Disease: MMX and Tailored Delivery to the Gut. Fiorino, G.; Fries, W.; De La Rue, S. A.; Malesci, A. C.; Repici, A.; Danese, S. // Current Medicinal Chemistry;Jun2010, Vol. 17 Issue 17, p1851 

    Inflammatory bowel diseases are chronic diseases that affect the gastrointestinal tract. Mesalamine, corticosteroids, immunosuppressants and biological agents are currently used to treat these diseases. Due to inadequacies of the currently available delivery systems, a large number of patients...

  • Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Selby, Lisbeth; Hoellein, Andrew; Wilson, John; Wilson, John F // Digestive Diseases & Sciences;Mar2011, Vol. 56 Issue 3, p819 

    Background and Aims: Those with chronic diseases, including inflammatory bowel disease (IBD), often do not receive preventive care at the same rate as the general population. Attitudes of primary care providers could be key factors in the receipt of preventive care.Methods:...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics